Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Share-based Compensation (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Share-based Compensation data on record, last reported at $3.2 million in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 51.36% year-over-year to $3.2 million; the TTM value through Sep 2025 reached $42.5 million, up 110.95%, while the annual FY2024 figure was $32.6 million, 91.55% up from the prior year.
  • Share-based Compensation reached $3.2 million in Q3 2025 per FBIO's latest filing, down from $16.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $16.8 million in Q2 2025 and bottomed at $3.2 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $6.2 million, with a median of $5.0 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: surged 337.1% in 2024, then tumbled 51.36% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $7.0 million in 2021, then decreased by 21.76% to $5.5 million in 2022, then tumbled by 32.73% to $3.7 million in 2023, then soared by 337.1% to $16.2 million in 2024, then tumbled by 80.25% to $3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $3.2 million in Q3 2025, $16.8 million in Q2 2025, and $6.3 million in Q1 2025.